Michael Thomas
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer Research top 0.5%
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
Papers in
-
- Lung Cancer Treatments and Mutations 149
- Lung Cancer Diagnosis and Treatment 85
- Brain Metastases and Treatment 17
- Oncology 112
- Lung Cancer Research Studies 52
- Cancer Immunotherapy and Biomarkers 34
- Cancer survivorship and care 17
- Co-authors
- Wolfgang E. Berdel (16 shared papers)Thomas Muley (59 shared papers)Carsten Müller‐Tidow (6 shared papers)Hubert L. Serve (6 shared papers)Sven Diederichs (5 shared papers)Paul M. Schneider (4 shared papers)Burkhard Brandt (6 shared papers)Etmar Bulk (3 shared papers)
- Journals
- Lung Cancer (36 papers)Annals of Oncology (27 papers)Journal of Thoracic Oncology (18 papers)International Journal of Cancer (13 papers)Cancers (13 papers)
- Partner nations
- GermanyUnited StatesSpain
In The Last Decade
Michael Thomas
363 papers receiving 21.9k citations
Michael Thomas's Hit Papers
Peers
Comparison fields: 5 of 141
- Pulmonary and Respiratory Medicine 12k
- Cancer Research 3k
- Oncology 4.2k
- Pharmacy 181
- Molecular Biology 2k
Countries citing papers authored by Michael Thomas
This map shows the geographic impact of Michael Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Thomas more than expected).
Fields of papers citing papers by Michael Thomas
This network shows the impact of papers produced by Michael Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Thomas. The network helps show where Michael Thomas may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Thomas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 383 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer Hit paper breakdown → | 2013 | 2903 |
| 2 | MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer Hit paper breakdown → | 2003 | 1930 |
| 3 | Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer Hit paper breakdown → | 2014 | 1251 |
| 4 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Hit paper breakdown → | 2014 | 1059 |
| 5 | Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 743 |
| 6 | The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival Hit paper breakdown → | 2012 | 598 |
| 7 | Early palliative care for adults with advanced cancer Hit paper breakdown → | 2017 | 570 |
| 8 | PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2013 | 506 |
| 9 | Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Hit paper breakdown → | 2012 | 496 |
| 10 | 2002 | 424 | |
| 11 | Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial Hit paper breakdown → | 2016 | 402 |
| 12 | 2010 | 377 | |
| 13 | 2015 | 340 | |
| 14 | Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study Hit paper breakdown → | 2021 | 328 |
| 15 | 2008 | 266 | |
| 16 | 2011 | 253 | |
| 17 | 2010 | 243 | |
| 18 | 1998 | 228 | |
| 19 | 2012 | 179 | |
| 20 | 2004 | 176 |
About Michael Thomas
Michael Thomas is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Public Health, Environmental and Occupational Health and Molecular Biology, having authored 383 papers that have together received 22.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (149 papers), Lung Cancer Diagnosis and Treatment (85 papers), Lung Cancer Research Studies (52 papers), Cancer Immunotherapy and Biomarkers (34 papers), Palliative Care and End-of-Life Issues (29 papers), Brain Metastases and Treatment (17 papers), Cancer survivorship and care (17 papers) and Cancer Genomics and Diagnostics (17 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (12k citations), Cancer Research (3k citations), Oncology (4.2k citations), Pharmacy (181 citations) and Molecular Biology (2k citations). Michael Thomas has collaborated with scholars based in Germany, United States and Spain. Frequent co-authors include Wolfgang E. Berdel, Thomas Muley, Carsten Müller‐Tidow, Hubert L. Serve, Sven Diederichs, Paul M. Schneider, Burkhard Brandt, Etmar Bulk, Ralf Metzger and Albrecht Stenzinger. Their work appears in journals such as Lung Cancer, Annals of Oncology, Journal of Thoracic Oncology, International Journal of Cancer and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.